CIGB 552

Drug Profile

CIGB 552

Alternative Names: CIGB552

Latest Information Update: 25 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
  • Class Antineoplastics; Apoptosis regulatory proteins; Peptides
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 24 Feb 2016 CIGB 552 is available for licensing in Cuba and other unknown countries as of 01 Dec 2014. http://gndp.cigb.edu.cu
  • 15 Sep 2015 Phase-I clinical trials in Cancer in Cuba (SC) (RPCEC00000196)
  • 20 Nov 2014 Preclinical trials in Cancer in Cuba (SC) prior to November 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top